

## Index to Volume 3

### Author Index

- Addiego, J. E., S160  
Ahn, C. H., 1028  
Ahn, S., 1028  
Ahn, S. S., 1028  
Aisenberg, A. C., S144  
Allegro, G. M., 98  
Allo, M., S273  
Ammann, A. J., S160, S179  
Amsbaugh, D. F., 332  
Andrews, C., S108  
Aranda, C., S183  
Armstrong, J., S273  
Ashbaugh, P., 914  
Austrian, R., 183, S1  
Bailey, M. C., 1035  
Baker, P. J., 332  
Bando, K., 885  
Barrett, D. J., S179  
Bartlett, J. G., 535  
Bartlett, M. S., 1139  
Bastille, A., 84  
Bates, J. H., 949  
Beauchamp, D., 84  
Bentley, D. W., S61, S71  
Berberich, F. R., S133  
Bergan, T., 45, 396  
Bergeron, M. G., 84  
Berwald, L. G., 871, 1024  
Bodey, G. P., S259  
Brachman, P. S., 640, 783  
Bratton, L., S113  
Brennan, P. J., 905  
Brennan, R. O., 98  
Brook, I., 470  
Broome, C. V., 277, S82  
Brown, W., 154  
Browne, R., S273  
Brummett, R. E., S216  
Bullen, J. J., 1127  
Bundtzen, R. W., 28  
Caldes, G., 332  
Campbell, S. C., 150  
Carlson, A. J., Jr., S31  
Cave, M. D., 949  
Chakraborty, A. K., 1060  
Chap, T. L., S168  
Chaparas, S. D., 934  
Cherubin, C. E., 1105  
Chodosh, S., 140  
Christianson, L., S183  
Citron, D. M., 599  
Clausen, J., 117  
Cohen, M. S., 565  
Cohn, D. L., 28  
Collins, F. M., 981  
Content, J., 1186  
Coonrod, J. D., 310  
Corpe, R. F., 1064  
Cosio, F. G., S168  
Counts, G., 166  
Cox, R. S., S133  
Craig, W. A., I, 28, 171  
Crawford, J. T., 949  
Cruse, P., 734  
Cunha, B. A., S269  
Dalovisio, J. R., 1068  
Damle, P. B., 1060  
David, H. L., 878  
Davidson, P. T., 816, 973, 1052, 1060  
Davis, A. L., S183  
Davis, B. I., 132  
De Clercq, E., 1186  
Delgin, J. M., S269  
Derynck, R., 1186  
Devos, R., 1186  
Digranes, A., 125, 396  
Donaldson, S. S., S133  
Donowitz, L. G., 701, 716  
Douglas, R. M., 233  
Ebright, J., S273  
Edwards, L., 166  
Egger, M. J., 492  
Egoz, N., 649  
Eickhoff, T. C., 798  
Engel, H. W. B., 871, 1024  
Epstein, L., 785  
Facklam, R. R., 277  
Faich, G., 683  
Falkinham, J. O., III, 990  
Feder, H. M., Jr., 479  
Fekety, R., S273  
Fiers, W., 1186  
File, T. M., Jr., 121, 154  
Finegold, S. M., 150, 599  
Finland, M., 354, 812  
Fisch, G. R., S113  
Fisher, K. A., 708, 716  
Fraser, B. A., 323  
Freeman, J., 658, 668  
Gallin, J. I., 1196  
Gangadharam, P. R., 973  
Garcia, E., 212  
Gentry, L. O., 150, 166  
George, W. L., 599  
Geraci, J. E., S250  
Gerber, A. U., 28, 171  
Giebink, G. S., 342, S43, S168  
Ginsberg, M. B., 683  
Ginsburg, C. M., 117  
Gleason, C., 154  
Glenn, J., 1151  
Goble, M., 1052  
Gorbach, S. L., 535  
Greenblatt, D. J., S230  
Griffith, R. S., S200  
Gröschel, D. H., 1251  
Gruft, H., 990  
Gump, D. W., S289  
Ha, K., S71  
Hahn, H., 1221  
Haley, R. W., 781, 783  
Havelar, A. H., 1024  
Haverkamp, J., 871  
Hellum, K. B., 125, 396  
Helms, K. K., 166  
Hilleman, M. R., S31  
Himes, E. M., 960  
Holbrook, K., 683  
Hornick, R. B., 1251  
Howie, V. M., S119  
Hoyt, J. W., 701  
Hsu, K. H. K., 1075  
Hurst, G. A., 1028  
Igra-Siegman, Y., 397  
Iravani, A., 159  
Ito, T., 997  
Izard, M. W., S269  
Jenkins, P. A., 862, 1021  
Jenner, E. A., 770  
Johnston, R. B., Jr., 282  
Jones, D. B., 898, 1068  
Jørgensen, J. B., 979  
Kallings, J. O., 721  
Kamforin, L. E., 408, 1104  
Kaminski, Z. C., 397  
Kapila, R., 397  
Kaplan, H. S., S133  
Karaseva, V., 1040, 1081  
Karczag, E., 1040  
Karson, A. G., 960  
Karma, P., S124  
Kaufmann, S. H. E., 1221  
Kawakami, K., 997  
Khanijo, V., 1052  
King, T. C., 627  
Kirby, B. D., 599  
Kirby, W. M. M., I, S236  
Kishore, R., 1179  
Kita, N., 997  
Klastersky, J., 74  
Kleeberg, H. H., 1008  
Klein, J. O., 246, S113  
Kondo, H., 997  
Kornfeld, S. J., 521  
Korzeniowski, O. M., 98  
Kottek, S. S., 636  
Kovaleva, T. P., 408, 1104  
Krogstad, D. J., 627, S230  
Kubar, O. I., 408, 1104  
Kunin, C. M., 4, 745  
Kurasawa, T., 885  
Kuse, A., 997

- Kuze, F., 885  
 Lagrange, P. H., 422  
 Landesman, S. H., S184  
 Le, C. T., S43  
 Lee, C.-J., 323, S51  
 Lee, Y., 885  
 LeFrock, J. L., 159  
 Leinonen, M., S124  
 Levine, J. I., 701  
 Lin, K.-J., 323  
 Lin, K.-T., S51  
 Lindeboom, B. W., 1024  
 Lopez, R., 212  
 Louie, T. J., 535  
 Louria, D. B., 397  
 Lowbury, E. J. L., 728  
 Lowell, J. R., 1028  
 Lusk, R., S273  
 Mackowiak, P. A., 508  
 Maderazo, E. G., 479  
 Maekawa, N., 885  
 Maesen, F. P. V., 132  
 Magnusson, M., 944  
 Mäkelä, P. H., S124  
 Mamot, K., S71  
 Mankiewicz, E., 926  
 Marisk, F. J., 716  
 Martone, W. J., 701, 708  
 Mathieu, O. R., S113  
 Matsuda, N., 997  
 Mattie, H., 19  
 McCalmon, R. T., 1060  
 McCarthy, C., 914  
 McClatchy, J. K., 867  
 McConnell, K. B., S108  
 McCracken, G. H., Jr., 117, S282  
 McDonald, P. J., 38  
 McGowan, J. E., Jr., 658, 668, 760, 790  
 McLean, A. A., S31  
 Meissner, G., 813, 953  
 Miao, L., 683  
 Michaeli, D., 649  
 Michel, J., 678, 754  
 Miller, G. B., 701  
 Moellering, R. C., Jr., S230  
 Mogabgab, W., 150, 159  
 Mombelli, G., 74  
 Moon, D., S71  
 Moore, L., S71  
 Moulding, T. S., 1052  
 Moxon, E. R., 354  
 Nakajima, N., 997  
 Nel, E. E., 1013  
 Nelson, J. D., S282  
 Neu, H. C., 12, 110  
 Neumann, H. H., 1255  
 Nightingale, C. H., S269  
 Onderdonk, A. B., 535  
 Osier, C., 479  
 Osterman, C. A., 701, 708  
 Pankey, G. A., 154, 1068  
 Parker, B. C., 990  
 Paacock, J. E., Jr., 701  
 Pennington, J. E., 67  
 Pezzia, W., 1035  
 Pfeiffer, R. R., S205  
 Plaut, A. G., S21  
 Ploussard, J. H., S119  
 Poirier, A., 84  
 Poletto, P., S71  
 Porter, P. J., S113  
 Pratt, P. F., 973  
 Prescott, B., 332  
 Pruul, H., 38  
 Pukander, J., S124  
 Quintiliani, R., S269  
 Ramakrishnan, C. V., 1090  
 Raleigh, J. W., 1035  
 Remaut, E., 1186  
 Remington, J. S., 492  
 Richard, G. A., 159  
 Rifkin, G., S273  
 Riley, I. D., 233  
 Ronda, C., 212  
 Root, R. K., 565  
 Rosenberg, E. W., 170  
 Rosenzweig, D. Y., 1046  
 Rudensky, B., 754  
 Runyon, E. H., 819, 1098  
 Sabin, A. B., 548  
 Sacks, T., 635, 678, 754  
 Salstrom, S.-J., 121  
 Saman, E., 1186  
 Sande, M. A., 98, 701, S240  
 Sansonetti, P., 422  
 Schaad, U. B., S282  
 Scheld, W. M., 98  
 Schiffman, G., 224, S18, S97, S108, S133, S160, S168, S183, S184  
 Schlössinger, D., 637  
 Schlueter, D. P., 1046  
 Schreiner, A., 125, 396  
 Sell, S. H., S97, S108  
 Semmelweis, I. P., 808  
 Sen, P., 397  
 Shapiro, M., 678, 754  
 Shimoide, H., 997  
 Shirota, N., 997  
 Siber, G. R., S144  
 Silva, J., S273  
 Silverblatt, J., 1035  
 Simchen, E., 678, 683, 754  
 Simpson, G. L., 492  
 Sjögren, I., 1084  
 Skatrud, J., 150  
 Sloyer, J. L., Jr., S119  
 Sparling, P. F., 166  
 Spika, J. S., S43, S168  
 Springett, A., S71  
 Sriyabhaya, N., 1085  
 Stanssens, P., 1186  
 Starobin, S. G., S113  
 Stashak, P. W., 332  
 Stinson, E. B., 492  
 Sutter, V. L., 599  
 Szu, S., 323  
 Tager, I. B., 683  
 Tamura, M., 997  
 Tan, J. S., 121  
 Tarlin, L. D., S113  
 Tavernier, J., 1186  
 Teele, D. W., S113  
 Terry, B. A., 738  
 Thoen, C. O., 960  
 Thompson, J., S97  
 Thys, J. P., 74  
 Tight, R. R., 1139  
 Timpe, A., 1098  
 Tomasz, A., 190, 267  
 Toshniwal, R., S273  
 Toth, E. A., 1035  
 Tsukamura, M., 829, 841, 997  
 Turnipseed, S. A., S224  
 Vaughn, W. K., S97, S108  
 Vella, P. P., S31  
 Volckaert, G., 1186  
 Vosti, K. L., S133  
 Wagner, K. F., 166  
 Wallace, R. J., Jr., 898, 1068  
 Wara, D. W., 299, S160  
 Wara, W. M., S160  
 Ward, J., 254  
 Watanakunakorn, C., S210  
 Watson, S. R., 991  
 Wayne, L. G., 822  
 Weibel, R. E., S31  
 Weiszfeiler, J. G., 1040, 1081  
 Weitzman, S. A., S144  
 Wenzel, R. P., 701, 708, 716  
 Wetherall, B. L., 38  
 Wieten, G., 871  
 Wilson, W. R., S250  
 Winkelstein, J. A., 289  
 Wise, R. I., S199, S293  
 Wiss, K., 898  
 Wold, J. S., S224  
 Wolinsky, E., 1025  
 Wongwatana, S., 1085  
 Woodhour, A. F., S31  
 Wright, P. F., S97, S108  
 Yamamoto, Y., 997  
 Yoneda, K., 310  
 Yoshimoto, K., 997  
 Younes, R. P., S113  
 Zak, O., 98  
 Zighelboim, S., 267  
 Zlydnikov, D. M., 408, 1104  
 Zweighaft, T., 117

## Subject Index

- Actinomycetoma  
 case report and literature review, 1139  
 surgical and medical therapy for, 1139
- Amikacin, for treatment of infection with *M. fortuitum* and *M. chelonae*, 1068
- Aminoglycosides  
 intermittent vs. continuous administration, 74, 84  
 in treatment of bronchopulmonary infections due to gram-negative bacteria, 74
- Amoxicillin  
 vs. bacampicillin in treatment of urinary tract infection, 159  
 levels in human blood and interstitial fluid after iv administration, 121
- Ampicillin  
 and bacampicillin, pharmacokinetics in infants and children, 117  
 vs. bacampicillin in treatment of bacterial infections of lower respiratory tract, 150  
 vs. bacampicillin in treatment of gonorrhea, 166  
 four times daily vs. bacampicillin twice daily in treatment of bronchitis, 140  
 levels in human blood and interstitial fluid after iv administration, 121
- Antibiotic levels, in human blood and interstitial fluid after administration of drugs, 121
- Antibiotic prophylaxis for prevention of infection in cancer patients, in combination with use of protected environments, S259
- Antibiotic resistance, of *Salmonella*, 1105
- Antibiotic-associated enterocolitis  
 in hamsters, S273  
 treatment with vancomycin, S273
- Antimicrobials. *See also* Antimicrobial agents; *names of specific agents*  
 evaluation of usage in hospitals, 745  
 penetration into respiratory secretions, 67  
 for surgical prophylaxis, 745, 754
- Antigens  
 human leukocyte, association with *M. intracellulare* disease, 1060  
 typing, structures of, for atypical mycobacteria, 905
- Antimicrobial agents. *See also* Antibiotics; *names of specific agents*  
 assessment of combinations, 627  
 continuous vs. intermittent administration  
 therapy of *S. pneumoniae* meningitis in rabbits, and post-antibiotic effect, 98  
 tissue penetration and efficacy, 84  
 in treatment of bronchopulmonary infections due to gram-negative bacteria, 74  
 dosage schedules and pharmacokinetics  
 historical review, 4  
 in infections at different sites, 12  
 efficacy of 29 regimens in experimental intraabdominal sepsis, 535  
 kinetics of action, 19  
 pharmacokinetics of tissue penetration, 45
- Bacampicillin  
 administered twice daily, worldwide experience, 171  
 vs. amoxicillin  
 for skin and soft tissue infections, 170  
 in treatment of urinary tract infections, 159  
 and ampicillin, in infants and children, 117  
 vs. ampicillin, penicillin V, and amoxicillin in treatment of tonsillitis and/or pharyngitis due to  $\beta$ -hemolytic streptococci, 154  
 vs. ampicillin, in treatment of bacterial infections of lower respiratory tract, 150  
 levels in human blood and interstitial fluid after oral administration, 121  
 pharmacokinetics, 110  
 of ampicillin in serum and dermal suction blisters after oral administration, 125  
 pulse dosing in treatment of acute exacerbations of chronic bronchitis, 132  
 single dose, vs. ampicillin in treatment of gonorrhea, 166  
 twice daily, vs. ampicillin four times daily in treatment of bronchitis, 140
- Bacille Calmette-Guérin, use in study of phage conversion and immunogenic potential, 926
- Bacteremia, *Klebsiella*, in newborn intensive care unit, caused by contaminated breast milk, 716
- Bronchial secretions, penetration of antibiotics, 67
- Bronchitis, antibiotic therapy and pharmacokinetics, 67, 74, 84, 132, 140
- Burn units, and nosocomial infections, 721, 728
- Cell-mediated immunity  
 to *M. leprae*, 422  
 role in bacterial infections, 1221
- Chemotaxis, abnormal phagocytic, 1196
- Chloramphenicol, current usage, efficacy, toxicity, and susceptibilities of pathogens, 479
- Chlorination of water, alternatives to, 1255
- Complement, role in defense against *S. pneumoniae*, 289, 310
- Cytomegalovirus infections following renal transplantation, review, 1151
- Diabetes mellitus, and response to pneumococcal polysaccharide vaccine, S184
- Doxycycline, for treatment of infection with *M. fortuitum* and *M. chelonae*, 1068
- Drug resistance, patterns and mechanisms in atypical mycobacteria, 878
- Endocarditis, staphylococcal and streptococcal, treatment with vancomycin, S250
- Eosinophils and neutrophils, human, microbicidal mechanisms, 565
- Epidemiology, of atypical mycobacterial infection  
 lung disease  
 due to nontuberculous mycobacteria in Japan, 997  
 in South India, 1090  
 in Thailand, 1085  
*M. avium-intracellulare* serovars in South Africa, 1013  
*M. kansasii* infections in The Netherlands, 1024  
 mycobacteriosis in eastern United States, 990  
 nontuberculous infections in Sweden, 1084

- nontuberculous mycobacteria in South Africa, 1008  
 use of seroagglutination test, 867
- Epidemiology, of *S. pneumoniae* disease, 233, 277  
 in infants and children, 246  
 with antibiotic-resistant pneumococci, 254, 267
- Fever, effects on pathogenic microorganisms, teleologic implication, 508
- Genetic agents causing variation in mycobacteria, 926
- Gonorrhea, bacampicillin vs. ampicillin therapy, 166
- Gram-negative anaerobic bacilli, role in infection and susceptibility to antimicrobial agents, *Fusobacterium* and other genera, 599
- Hodgkin's disease, response of patients to pneumococcal polysaccharide antigen, S133, S144, S160
- IgA proteases, bacterial, and secretory immunity, 521
- Immunity  
 cell-mediated  
   to *M. leprae*, 422  
   role in bacterial infections, 1221  
 and pneumococcal polysaccharide vaccines, S1-S197  
 secretory, and bacterial IgA proteases, 521  
 to *S. pneumoniae*  
   in mice and humans, 224  
   protection and pathogenesis of tissue damage, 282  
   response to polysaccharide antigens, 224, 323  
     regulation by thymus-derived cells, 332  
   role of complement, 289, 310  
   role of opsonins, 310  
   role of spleen, 224, 299  
   vaccination of chinchillas, 342
- Immunocompromised hosts (cardiac allograft recipients), no-cardiac infections, 492
- Immuno-electrophoresis, modified rocket- and cross-, study of antigenic relationships among mycobacteria, 934
- Immunosuppression, and response to pneumococcal polysaccharide antigen, S160, S168
- Infections, bacterial  
   bronchopulmonary, antibiotic therapy and penetration into bronchial secretions, 67, 74  
   role of levels of lactic acid in body fluids in detection, 470
- Influenza, therapy and prophylaxis with rimantadine, studies in USSR, 408
- Intensive care units, nosocomial infections, 716, 721
- Interferon, human fibroblast, isolation and characterization of gene and its expression in *Escherichia coli*, 1186
- Iron, significance in infection, 1127
- Isotopes, comparison of  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{33}\text{C}$ , and  $^{75}\text{Se}$  for labeling microorganisms, 1179
- Klebsiella*, bacteremia in newborn intensive care unit, caused by contaminated breast milk, 716
- Lactic acid, levels in body fluids, role in detection of bacterial infection, 470
- Leprosy, spectrum of disease and immunology, 422
- Leukocyte enhancement, increased susceptibility of antibiotic-treated bacteria to leukocytes, 38
- Lung infection  
   with atypical mycobacteria, immune responses, 981  
   chronic obstructive, response of patients to pneumococcal polysaccharide vaccine, S183  
   due to *M. avium-intracellulare*, 1046  
   spectrum of disease, 1046  
   surgical management, 1064  
   due to *M. kansasii*  
     efficacies of various drugs, 1028  
     treatment with rifampin, 1035  
   due to nontuberculous mycobacteria, epidemiology in Japan, 997  
   role of atypical mycobacteria, 1090, 1098 (classic paper), 1085  
   surgical management of infection with *M. avium-intracellulare*, 1064
- Lymphadenitis, diagnosis and treatment, 1075
- Malignancies, and spleen, role in immune response to *S. pneumoniae* polysaccharide antigens, 224
- Mass spectrometry, pyrolysis techniques, use in taxonomy and identification of mycobacteria, 871
- Meningitis, bacterial, treatment with vancomycin, alone and in combination, S289, S293
- Mycobacteria  
   agents causing variation, 926  
   antigenic relationships studied by modified-rocket and crossed immuno-electrophoresis, 934  
   definition of terms, 816, 819  
   epidemiology of opportunist infections in Wales, 1021  
   infections due to two or more species, 1081  
   methods of identification and differentiation, 841  
     numerical, 822, 829  
     lipid analysis for speciation, 862  
     pyrolysis mass spectrometry, 871  
     sensitins, 944  
     thin-layer chromatography, 862  
   nontuberculous, epidemiology  
     of lung disease in Japan, 997  
     in South Africa, 1008  
     in Sweden, 1084  
     use of seroagglutination test, 867  
   overview, 819
- Mycobacteria, atypical. *See also species names*  
   animal models in study of infection, 953  
   differentiation from tuberculous infections, 1075  
   disease in domestic and exotic animals, 960  
   epidemiology in eastern United States, 990  
   infections in children, 1075  
   lung infection, immune response to, 981  
   pathogenicity and immunogenicity for calves, 979  
   patterns and mechanisms of multiple-drug resistance, 878  
   role in human lung disease, 1085, 1090, 1098 (classic paper)  
   structures of typing antigens, 905  
   susceptibility  
     to antituberculous drugs, 885  
     to various drug combinations, 885  
   symposium, 813-1104
- Mycobacterium avium*, factors affecting the cell cycle, 914
- Mycobacterium avium-intracellulare*  
   characterization of plasmids, 949  
   lung infection  
     spectrum of clinical disease, 1046  
     surgical management, 1064  
   serovars isolated in South Africa, 1013
- Mycobacterium avium-intracellulare-scrofulaceum*  
   seroagglutination test in epidemiologic studies, 867

- structures of typing antigens, 905
- Mycobacterium avium* complex, disease in animals, 960
- Mycobacterium chelonae*
  - infection treated with amikacin and doxycycline, 1068
  - susceptibility to sulfonamides, 898
- Mycobacterium fortuitum*
  - infection treated with amikacin and doxycycline, 1068
  - susceptibility to sulfonamides, 898
- Mycobacterium intracellulare*, infection
  - association with human leukocyte antigens, 1060
  - development of animal model, 973
  - treatment with multiple drug chemotherapy, 1052
- Mycobacterium kansasii*
  - infections in The Netherlands, 1024
  - lung disease
    - efficacies of various drugs, 1028
    - treatment with rifampin, 1035
- Mycobacterium simiae*, isolation and comparison to related mycobacteria, 1040
- Mycobacterium tuberculosis*, infections
  - in combination with atypical mycobacteria, 1081
  - vs. tuberculous disease, 1025
- Nephrotic syndrome, and response to pneumococcal polysaccharide vaccine, S168, S184
- Neutrophils and eosinophils, human, microbicidal mechanisms, 565
- Nocardia*, infections in immunocompromised cardiac allograft recipients, 492
- Nosocomial infections
  - colonization with *P. cepacia*, 708
  - control, role of hospital administrator, 783, 785
  - cost-benefit analysis, 790
  - control and surveillance, 770, 775
  - environmental factors, 760
  - evaluation of antibiotic usage, 745, 754
  - hospital epidemiology
    - rates, case-finding and interpretation, 658
    - time and accuracy of estimation, 668
  - in a general hospital, surveillance, 649
  - in intensive care units, 716, 721
  - prevention by use of management techniques, 738
  - procedure-related, identification in high-risk patients, 701
  - statewide prospective surveillance system for identification and prevention, 683
  - surveillance and intervention in specific problem areas, 721
  - overview, 640
  - summary, 798
- Nosocomial infection control, a symposium, 635-811
- Otitis media
  - acute, recurrent, prevention by pneumococcal polysaccharide vaccine, S113, S119, S124
  - due to *S. pneumoniae*
    - in chinchillas, 342
    - in human children, 246
- Ototoxicity, antibiotic-diuretic interventions in guinea pig model, S216
- Pasteurization, as alternative to chlorination, 1255
- Penicillin, phenoxymethyl, levels in human blood and interstitial fluid after oral administration, 121
- Penicillin V, vs. bacampicillin and amoxicillin in treatment of tonsillitis and/or pharyngitis, 154
- Phagocytic cells
  - abnormal chemotaxis, pathophysiology, clinical manifestations, and management of patients, 1196
  - cell-mediated immunity of, 1221
  - role in infection, 565
- Pharmacokinetics
  - of antimicrobial agents, 4, 12, 19, 45
  - of ampicillin in serum and dermal suction blisters after oral administration of bacampicillin, 125
  - of bacampicillin and ampicillin in infants and children, 117
- Plasmids, characterization, from strains of *M. avium-intracellulare*, 949
- Pneumococcal polysaccharides, capsular, analysis of antibody, 543
- Pneumococcal polysaccharide vaccine
  - age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines, S31
  - chemistry and immunochemistry, S18
  - clinical studies in infants
    - efficacy and effect on nasopharyngeal carriage, S108
    - prevention of recurrent otitis media, S113, S119, S124
    - reactogenicity and immunogenicity of two polyvalent vaccines, S97
  - control and immunogenicity of polysaccharides, S51
  - cross-reactions and immunology, S18
  - efficacy, S82
  - IgG and IgM response of patients with sickle cell disease, S179, S184
  - in the institutionalized elderly, S61, S184
  - design and results of a nonrandomized trial, S71
  - response of patients
    - with chronic obstructive pulmonary disease, S183
    - with diabetes mellitus, S191
    - with Hodgkin's disease, S133, S144, S160, S184
    - with nephrotic syndrome, S168
    - with renal failure and/or transplant, S168, S184
    - with splenectomy, S168, S184
    - with systemic lupus erythematosus, S184
  - serum antibody responses of high-risk children and adults, S168, S184. *See also specific risk factors, e.g. Diabetes mellitus*
  - symposium, S1-S197
  - toxicity, S184
- Poliomyelitis, paralytic, old dogmas and new perspectives, 543
- Poliovirus vaccines, and "vaccine-associated" paralytic disease, 543
- Polysaccharide antigens, of *S. pneumoniae*, immune response of mice and humans, 224, 323
- Postantibiotic effect
  - leukocyte enhancement, increased susceptibility of antibiotic-treated bacteria to leukocyte activity, 38
  - suppression of growth of bacterial species by various antibiotics, 29
- Pseudomonas cepacia*, epidemic of nosocomial colonization, 708
- Pulmonary disease. *See* Lung infection
- Pulse dosing
  - of antimicrobial agents, especially bacampicillin, 1-177



- theory and applications, 1
- Radiolabeled microorganisms, comparison of different isotopes, 1179
- Renal failure and/or transplant, and response to pneumococcal polysaccharide vaccine, S168, S184
- Renal transplant patients, incidence and epidemiology of cytomegaloviral infections, 1151
- Rimantadine, use in USSR, 408
- Salmonella*, antibiotic resistance in Europe and the United States, 1105
- Salmonellosis, transmission of, 1105
- Schaefer, W. B.  
Memorial Lecture, 953  
tribute, 813
- Sensitins, use in classification and identification of mycobacteria, 944
- Sepsis, experimental intraabdominal, comparison of efficacies of 29 antimicrobial regimens, 535
- Sickle cell disease, IgG and IgM response to pneumococcal polysaccharide vaccine, S179
- Spleen, role in immune response to *S. pneumoniae*, 224, 299
- Splenectomy, and response to pneumococcal polysaccharide vaccine, S168, S184
- Staphylococcal infections  
in children, treatment with vancomycin, S282  
treatment with vancomycin, S236, S293
- Staphylococcus aureus*, endocarditis, rabbit model, evaluation of antimicrobial agents, S240, S293
- Staphylococcus aureus*, infections, treatment with vancomycin, S200
- Streptococcus*, viridans group, endocarditis, rabbit model, evaluation of antimicrobial agents, S240, S293
- Streptococcus pneumoniae*  
bacteriophages, 212  
biology, disease, and prevention, S1  
epidemiology of disease, 233, 277  
antibiotic-resistant pneumococci, 254, 267  
in infants and children, 246  
in Papua New Guinea, 233  
experimental infections in animals, 342, 354  
history of research since 1875, 183  
host defense  
complement and opsonins in serum and alveolar secretions of rats with pneumonia, 310  
protection and pathogenesis of tissue damage, 282  
regulation of response of thymus-derived cells to polysaccharide antigens, 232  
response of mice and humans to polysaccharide antigens, 224, 323  
role of complement, 289, 310  
role of spleen, 299  
otitis media in chinchillas, efficacy of vaccination, 342  
polysaccharide antigens, immune response of mice and humans, 224, 323  
polysaccharide vaccine, symposium, S1-S197  
summary of conference, 358  
surface components, 190  
symposia  
pneumococcal polysaccharide vaccine, S1-S197  
the pneumococcus, 183-395
- Strongyloides stercoralis*, hyperinfection syndrome, 397
- Sulfonamides, activity against *M. fortuitum* and *M. chelonae*, 898
- Surgery  
and nosocomial infections, 721, 728  
antibiotic prophylaxis, 745, 754
- Surgical wounds  
postoperative infection, multivariate analysis of determinants, basis for intervention, 678  
surveillance for infection, 734
- Synergy, of antimicrobial agents, and assessment of drug combinations, 627
- Systemic lupus erythematosus, and response to pneumococcal polysaccharide vaccine, S184
- Toxicity  
of chloramphenicol, and current clinical usage, 479  
of pneumococcal polysaccharide vaccine, S184
- Typhoid vaccination, introduction of, 1251
- Urinary tract infection, treatment with amoxicillin, bacampicillin, or penicillin V, 154
- Vancomycin  
absence of ototoxic effects in guinea pig model, S216  
adverse effects, S282, S293  
chemistry, S205, S293  
in combination with aminoglycoside, S210  
in combination with rifampin, S210  
history of development, S199, S200, S293  
introduction to symposium, S199  
for patients with renal insufficiency, S230  
penetration into cerebrospinal fluid, S289  
pharmacokinetics, S293  
in anephric patients, S269  
in normal subjects, S230, S269  
in patients with reduced renal function, S230, S269  
pharmacology and efficacy for staphylococcal infections in children, S282  
for prophylaxis  
in anephric patients, S269  
in patients with cancer, S259  
in patients with malignancy, S293  
in renal dialysis patients, S200  
in rabbit model of endocarditis due to *S. aureus* or viridans group streptococcus, S240  
spectrum and antibacterial action, S210, S293  
structure, S205  
summary of symposium, S293  
symposium, S199-S300  
toxicology, in laboratory animals, S224  
for treatment  
of antibiotic-associated enterocolitis, S273, S293  
of bacterial meningitis, S289, S293  
of infective endocarditis due to staphylococci or streptococci, S250, S293  
of *S. aureus* infections, S200  
of staphylococcal infections  
in children, S282  
severe, S236

## Reviews of Infectious Diseases

*An Official Publication of the Infectious Diseases Society of America*

Edward H. Kass, *Editor*  
John R. David, *Associate Editor*  
Sherwood L. Gorbach, *Associate Editor*  
Alice S. Huang, *Associate Editor*  
Dennis L. Kasper, *Associate Editor*  
Jerome O. Klein, *Associate Editor*

### EDITORIAL BOARD

Robert Austrian, Philadelphia, Pa.  
Michael M. Frank, Bethesda, Md.  
Lawrence R. Freedman, Los Angeles, Calif.  
D. Carleton Gajdusek, Bethesda, Md.  
King K. Holmes, Seattle, Wash.  
Harold J. Jennings, Ottawa, Canada

### INTERNATIONAL BOARD OF DIRECTORS

Jacques F. Acar, Paris, France  
Ralph van Furth, Leiden, The Netherlands  
C. H. Huang, Beijing, China  
Lars O. Kallings, Stockholm, Sweden  
Jean Klustersky, Brussels, Belgium

Mary M. Eichhorn Adams, *Assistant Editor*  
Nancy Kurz Voynow, *Managing Editor*  
Maureen A. Hayes, *Editorial Assistant*  
Louise L. Kittredge, *Editorial Assistant*  
Laura J. Liebler, *Editorial Assistant*

Richard T. Johnson, Baltimore, Md.  
Samuel L. Katz, Durham, N.C.  
Thomas C. Merigan, Jr., Stanford, Calif.  
Kenneth S. Warren, New York, N.Y.  
Frank E. Young, Rochester, N.Y.

P. Helena Mäkelä, Helsinki, Finland  
Francis O'Grady, Nottingham, England  
Theodore G. Sacks, Jerusalem, Israel  
David A. J. Tyrrell, London, England  
Yuichi Yamamura, Osaka, Japan

Volume 3  
January-December 1981

All rights reserved  
THE UNIVERSITY OF CHICAGO PRESS, CHICAGO  
THE UNIVERSITY OF CHICAGO PRESS LTD., LONDON S.W. 1

---

© 1981 BY THE UNIVERSITY OF CHICAGO  
PUBLISHED BIMONTHLY JANUARY-DECEMBER

---

Printed in U.S.A.



## Reviews of Infectious Diseases

Volume 3

January-February 1981

Number 1

### Contents

Participants .....	vi
Theory and Applications of Pulse Dosing: A Summary of the Symposium. WILLIAM M. M. KIRBY and WILLIAM A. CRAIG .....	1
Historical Background and Current Practices	
Dosage Schedules of Antimicrobial Agents: A Historical Review. CALVIN M. KUNIN .....	4
Current Practices in Antimicrobial Dosing. HAROLD C. NEU .....	12
Microbiologic Considerations	
Kinetics of Antimicrobial Action. H. MATTIE .....	19
Postantibiotic Suppression of Bacterial Growth. ROBERT W. BUNDTZEN, ANDREAS U. GERBER, DAVID L. COHN, and WILLIAM A. CRAIG .....	28
Postantibiotic Leukocyte Enhancement: Increased Susceptibility of Bacteria Pretreated with Antibiotics to Activity of Leukocytes. P. J. McDONALD, B. L. WETHERALL, and H. PRUUL .....	38
Pharmacologic Considerations	
Pharmacokinetics of Tissue Penetration of Antibiotics. TOM BERGAN .....	45
Penetration of Antibiotics into Respiratory Secretions. JAMES E. PENNINGTON .....	67
In Vivo Studies	
Comparative Studies of Intermittent and Continuous Administration of Aminoglycosides in the Treatment of Bronchopulmonary Infections Due to Gram-Negative Bacteria. J. KLASTERSKY, J. P. THYS, and G. MOMBELLI .....	74
Continuous vs. Intermittent Administration of Antimicrobial Agents: Tissue Penetration and Efficacy in Vivo. MICHEL G. BERGERON, DENIS BEAUCHAMP, ANDRÉ POIRIER, and ALAIN BASTILLE .....	84
Intermittent or Continuous Therapy of Experimental Meningitis Due to <i>Streptococcus pneumoniae</i> in Rabbits: Preliminary Observations on the Postantibiotic Effect in Vivo. MERLE A. SANDE, OKSANA M. KORZENIOWSKI, GEORGE M. ALLEGRO, ROBERT O. BRENNAN, OTOKAR ZAK, and W. MICHAEL SCHELD .....	98
Bacampicillin: Pharmacologic Studies	
The Pharmacokinetics of Bacampicillin. HAROLD C. NEU .....	110
Comparative Pharmacokinetics of Bacampicillin and Ampicillin Suspensions in Infants and Children. CHARLES M. GINSBURG, GEORGE H. MCCrackEN, JR., JOAN CLAHSSEN, and TERESA ZWEIGHAFT .....	117
Levels of Antibiotic in Human Blood and Interstitial Fluid After Oral Administration of Bacampicillin or Phenoxymethyl Penicillin and Intravenous Administration of Amoxicillin or Ampicillin. JAMES S. TAN, SARA-JANE SALSTROM, and THOMAS M. FILE, JR. ....	121

## Bacampicillin: Clinical Studies

Pharmacokinetics of Ampicillin in Serum and in Dermal Suction Blisters After Oral Administration of Bacampicillin. A. SCHREINER, T. BERGAN, K. B. HELLM, and A. DIGRANES.....	125
Pulse Dosing with Bacampicillin in Treatment of Acute Exacerbations of Chronic Bronchitis. F. P. V. MAESEN and B. I. DAVIES.....	132
Comparison of Bacampicillin Twice Daily and Ampicillin Four Times Daily in Treatment of Acute Exacerbations of Chronic Bronchitis. SANFORD CHODOSH.....	140
Controlled Comparative Trial of Bacampicillin and Amoxicillin in Therapy of Bacterial Infections of the Lower Respiratory Tract. SYDNEY M. FINEGOLD, LAYNE O. GENTRY, WILLIAM MOGABGAB, SAMMY C. CAMPBELL, and JAMES SKATRUD.....	150
A Comparative Study of Bacampicillin Hydrochloride, Penicillin V, and Amoxicillin in the Treatment of Acute Tonsillitis and/or Pharyngitis Due to $\beta$ -Hemolytic Streptococci. GEORGE A. PANKEY, CHARLES GLEASON, THOMAS M. FILE, JR., and WALTER BROWN.....	154
Bacampicillin vs. Amoxicillin for Treatment of Acute Infections of the Urinary Tract. GEORGE A. RICHARD, ABDOLLAH IRAVANI, JACK L. LEFROCK, and WILLIAM MOGABGAB.....	159
Clinical Evaluation of Single-Dose Oral Bacampicillin or Ampicillin in Therapy of Uncomplicated Gonorrhea. KENNETH F. WAGNER, GEORGE COUNTS, KING K. HOLMES, P. FREDERICK SPARLING, LAYNE O. GENTRY, and LARRY EDWARDS.....	166
A Comparative Study of Bacampicillin Hydrochloride Given Twice a Day and Amoxicillin Given Three Times a Day for Treatment of Skin and Soft Tissue Infections: Preliminary Observations. E. WILLIAM ROSENBERG.....	170
Worldwide Experience with Bacampicillin Administered Twice a Day. WILLIAM A. CRAIG and ANDREAS U. GERBER.....	171
Statement of Editorial Policy and Instructions to Authors.....	178

Volume 3

• March-April 1981 •

Number 2

## Contents

Participants.....	vi
Session I: The Pneumococcus	
Pneumococcus: The First One Hundred Years. ROBERT AUSTRIAN.....	183
Discussion.....	189
Surface Components of <i>Streptococcus pneumoniae</i> . ALEXANDER TOMASZ.....	190
Bacteriophages of <i>Streptococcus pneumoniae</i> . RUBENS LOPEZ, ERNESTO GARCIA, and CONCEPCION RONDA.....	212
Immune Responses to Pneumococcal Polysaccharide Antigens: A Comparison of the Murine Model and the Response in Humans. GERALD SCHIFFMAN.....	224
Discussion.....	232

## Session II: Epidemiology of Pneumococcal Disease

An Epidemiologic Approach to Pneumococcal Disease. IAN D. RILEY and ROBERT M. DOUGLAS.....	233
The Epidemiology of Pneumococcal Disease in Infants and Children. JEROME O. KLEIN.....	246
Antibiotic-Resistant <i>Streptococcus pneumoniae</i> : Clinical and Epidemiologic Aspects. JOEL WARD.....	254
Multiple Antibiotic Resistance in South African Strains of <i>Streptococcus pneumoniae</i> : Mechanism of Resistance to $\beta$ -Lactam Antibiotics. SONIA ZIGHELBOIM and ALEXANDER TOMASZ.....	267
Discussion.....	276
Epidemiology of Clinically Significant Isolates of <i>Streptococcus pneumoniae</i> in the United States. CLAIRE V. BROOME and RICHARD R. FACKLAM.....	277
Discussion.....	281

## Session III: Host Defense Against the Pneumococcus

The Host Response to Invasion by <i>Streptococcus pneumoniae</i> : Protection and the Pathogenesis of Tissue Damage. RICHARD B. JOHNSTON, JR.....	282
The Role of Complement in the Host's Defense Against <i>Streptococcus pneumoniae</i> . JERRY A. WINKELSTEIN.....	289
Discussion.....	298
Host Defense Against <i>Streptococcus pneumoniae</i> : The Role of the Spleen. DIANE W. WARA..	299
Discussion.....	309
Complement and Opsonins in Alveolar Secretions and Serum of Rats with Pneumonia Due to <i>Streptococcus pneumoniae</i> . J. DONALD COONROD and KOKICHI YONEDA.....	310
Chemical Structure of and Immune Response to Polysaccharides of <i>Streptococcus pneumoniae</i> . CHI-JEN LEE, BLAIR A. FRASER, SHOUSUN SZU, and KUEI-TANG LIN.....	323
Regulation of the Antibody Response to Pneumococcal Polysaccharide by Thymus-Derived Cells. PHILLIP J. BAKER, DIANA F. AMSBAUGH, PHILIP W. STASHAK, GEORGE CALDES, and BENJAMIN PRESCOTT.....	332
Discussion.....	341
The Pathogenesis of Pneumococcal Otitis Media in Chinchillas and the Efficacy of Vaccination in Prophylaxis. G. SCOTT GIEBINK.....	342
Discussion.....	353
Experimental Infections of Animals in the Study of <i>Streptococcus pneumoniae</i> . E. RICHARD MOXON.....	354

## Summary

Conference on the Pneumococcus: Summary and Comments. MAXWELL FINLAND.....	358
--	-----

## Classics in Infectious Diseases

The Significance of Pneumococcal Types. FRED. GRIFFITH.....	372
Errata (Bergan, T., 3:45-66; Schreiner, A., et al., 3:125-131).....	396

## Contents

Participants .....	Svi
Session I: Pneumococcal Disease and the Development and Chemistry of the Vaccine	
Some Observations on the Pneumococcus and on the Current Status of Pneumococcal Disease and Its Prevention. ROBERT AUSTRIAN .....	S1
Chemistry and Immunochemistry of the Pneumococcal Polysaccharide Vaccine with Special Reference to Cross-Reactions and Immunologic Factors. GERALD SCHIFFMAN .....	S18
Discussion .....	S27
Session II: Responses to Pneumococcal Vaccine	
<i>Streptococcus pneumoniae</i> Polysaccharide Vaccine: Age and Dose Responses, Safety, Persistence of Antibody, Revaccination, and Simultaneous Administration of Pneumococcal and Influenza Vaccines. MAURICE R. HILLEMAN, ALFRED J. CARLSON, JR., ARLENE A. McLEAN, PHILIP P. VELLA, ROBERT E. WEIBEL, and ALLEN F. WOODHOUR .....	S31
Summarized vs. Type-Specific Analysis of Antibody to Pneumococcal Capsular Polysaccharides. G. SCOTT GIEBINK, CHAP T. LE, and JOHN S. SPIKA .....	S43
Discussion .....	S47
Session III: Efficacy of Pneumococcal Vaccine	
Studies on Vaccine Control and Immunogenicity of Polysaccharides of <i>Streptococcus pneumoniae</i> . CHI-JEN LEE and KUEI-TANG LIN .....	S51
Discussion .....	S60
Pneumococcal Vaccine in the Institutionalized Elderly: Review of Past and Recent Studies. DAVID W. BENTLEY .....	S61
Pneumococcal Vaccine in the Institutionalized Elderly: Design of a Nonrandomized Trial and Preliminary Results. DAVID W. BENTLEY, KATHY HA, KENNETH MAMOT, DAVID MOON, LORRAINE MOORE, PATRICIA POLETTI, and AUDREY SPRINGETT .....	S71
Efficacy of Pneumococcal Polysaccharide Vaccines. CLAIRE V. BROOME .....	S82
Discussion .....	S89
Session IV: Efficacy Studies of Pneumococcal Vaccine in Infants and Children	
Clinical Studies of Pneumococcal Vaccines in Infants. I. Reactogenicity and Immunogenicity of Two Polyvalent Polysaccharide Vaccines. SARAH H. SELL, PETER F. WRIGHT, WILLIAM K. VAUGHN, JULIETTE THOMPSON, and GERALD SCHIFFMAN .....	S97
Clinical Studies of Pneumococcal Vaccines in Infants. II. Efficacy and Effect on Nasopharyngeal Carriage. PETER F. WRIGHT, SARAH H. SELL, WILLIAM K. VAUGHN, CLAUDIA ANDREWS, KATHRYN B. McCONNELL, and GERALD SCHIFFMAN .....	S108
Use of Pneumococcal Vaccine for Prevention of Recurrent Acute Otitis Media in Infants in Boston. DAVID W. TEELE, JEROME O. KLEIN, and the GREATER BOSTON COLLABORATIVE STUDY GROUP: LORNA BRATTON, GILBERT R. FISCH, OWEN R. MATHIEU, PHILIP J. PORTER, SIDNEY G. STAROBIN, LLOYD D. TARLIN, and ROBERT P. YOUNES .....	S113

Efficacy of Pneumococcal Polysaccharide Vaccine in Preventing Acute Otitis Media in Infants in Huntsville, Alabama. JOHN L. SLOYER, JR., JOHN H. PLOUSSARD, and VIRGIL M. HOWIE . . .	S119
A Study of the Pneumococcal Vaccine in Prevention of Clinically Acute Attacks of Recurrent Otitis Media. P. HELENA MÄKELÄ, MAIJA LEINONEN, JUHANI PUKANDER, and PEKKA KARMA .	S124
Discussion . . . . .	S131

#### Session V: Immunologic Response of High-Risk Patients to Pneumococcal Vaccine

Response to Pneumococcal Vaccine Among Children with Hodgkin's Disease. SARAH S. DONALDSON, KENNETH L. VOSTI, F. RALPH BERBERICH, RICHARD S. COX, HENRY S. KAPLAN, and GERALD SCHIFFMAN . . . . .	S133
Antibody Response of Patients with Hodgkin's Disease to Protein and Polysaccharide Antigens. GEORGE R. SIBER, SIGMUND A. WEITZMAN, and ALAN C. AISENBERG . . . . .	S144
Immunization of Immunosuppressed Patients with Pneumococcal Polysaccharide Vaccine. ARTHUR J. AMMANN, GERALD SCHIFFMAN, JOSEPH E. ADDIEGO, WILLIAM M. WAR, and DIANE W. WAR . . . . .	S160
Serum Antibody Responses of High-Risk Children and Adults to Vaccination with Capsular Polysaccharides of <i>Streptococcus pneumoniae</i> . G. SCOTT GIEBINK, CHAP T. LE, FERNANDO G. COSIO, JOHN S. SPIKA, and GERALD SCHIFFMAN . . . . .	S168
Pneumococcal Vaccine in Sickle Cell Disease: IgG and IgM Antibody Response. DOUGLAS J. BARRETT and ARTHUR J. AMMANN . . . . .	S179
Pneumococcal Antibodies in Patients with Chronic Obstructive Pulmonary Disease and Their Response to Pneumococcal Capsular Polysaccharides: Preliminary Results. ANNE L. DAVIS, CONRADO ARANDA, LYNN CHRISTIANSON, and GERALD SCHIFFMAN . . . . .	S183
Assessment of the Antibody Response to Pneumococcal Vaccine in High-Risk Populations. SHELDON H. LANDESMAN and GERALD SCHIFFMAN . . . . .	S184
Discussion . . . . .	S197

Volume 3

May-June 1981

Number 3

## Contents

### Review Articles

Syndrome of Hyperinfection with <i>Strongyloides stercoralis</i> . YARDENA IGRA-SIEGMAN, RAJENDRA KAPILA, PURNENDU SEN, SIGMUND C. KAMINSKI, and DONALD B. LOURIA . . . . .	397
Study of Rimantadine in the USSR: A Review of the Literature. D. M. ZLYDNIKOV, O. I. KUBAR, T. P. KOVALEVA, and L. E. KAMFORIN . . . . .	408
The Immunology of Leprosy: Speculations on the Leprosy Spectrum. P. SANSONETTI and P. H. LAGRANGE . . . . .	422
The Importance of Lactic Acid Levels in Body Fluids in the Detection of Bacterial Infections. ITZHAK BROOK . . . . .	470
Chloramphenicol: A Review of Its Use in Clinical Practice. HENRY M. FEDER, JR., CARL OSIER, and EUFRONIO G. MADERAZO . . . . .	479



Nocardial Infections in the Immunocompromised Host: A Detailed Study in a Defined Population. GARY L. SIMPSON, EDWARD B. STINSON, MARLENE J. EGGER, and JACK S. REMINGTON ..	492
Direct Effects of Hyperthermia on Pathogenic Microorganisms: Teleologic Implications with Regard to Fever. PHILIP A. MACKOWIAK .....	508
Secretory Immunity and the Bacterial IgA Proteases. STEPHEN J. KORNFELD and ANDREW G. PLAUT .....	521
Therapeutic Efficacy of 29 Antimicrobial Regimens in Experimental Intraabdominal Sepsis. JOHN G. BARTLETT, THOMAS J. LOUIE, SHERWOOD L. GORBACH, and ANDREW B. ONDERDONK ..	535
Paralytic Poliomyelitis: Old Dogmas and New Perspectives. ALBERT B. SABIN .....	543

Serial Features

The Microbicidal Mechanisms of Human Neutrophils and Eosinophils. RICHARD K. ROOT and MYRON S. COHEN .....	565
Gram-Negative Anaerobic Bacilli: Their Role in Infection and Patterns of Susceptibility to Antimicrobial Agents. II. Little-Known <i>Fusobacterium</i> species and Miscellaneous Genera. W. LANCE GEORGE, BARBARA D. KIRBY, VERA L. SUTTER, DIANE M. CITRON, and SYDNEY M. FINEGOLD .....	599

Hypothesis

The Assessment of Antimicrobial Combinations. THOMAS C. KING, DAVID SCHLESSINGER, and DONALD J. KROGSTAD .....	627
--	-----

Volume 3 • July-August 1981 • Number 4

Contents

Participants .....	vi
Introduction. THEODORE SACKS .....	635
The Hospital in Jewish History. SAMUEL S. KOTTEK .....	636
Session I	
Nosocomial Infection Control: An Overview. PHILIP S. BRACHMAN .....	640
A Program for Surveillance of Hospital-Acquired Infections in a General Hospital: A Two-Year Experience. NACHUM EGOZ and DAN MICHAELI .....	649
Methodologic Issues in Hospital Epidemiology. JONATHAN FREEMAN and JOHN E. MCGOWAN, JR.	
I. Rates, Case-Finding, and Interpretation .....	658
II. Time and Accuracy of Estimation .....	668
Multivariate Analysis of Determinants of Postoperative Wound Infection: A Possible Basis for Intervention. E. SIMCHEN, M. SHAPIRO, J. MICHEL, and T. SACKS .....	678



Rationale and Methods for a Statewide, Prospective Surveillance System for the Identification and Prevention of Nosocomial Infections. IRA B. TAGER, MICHAEL B. GINSBERG, ELISHEVA SIMCHEN, LILLIAN MIAO, KATHLEEN HOLBROOK, and GERALD A. FAICH. ....	683
Discussion .....	694

## Session II

Identification of Procedure-Related Nosocomial Infections in High-Risk Patients. RICHARD P. WENZEL, CHARLES A. OSTERMAN, LEIGH G. DONOWITZ, JOHN W. HOYT, MERLE A. SANDE, WILLIAM J. MARTONE, JAMES E. PEACOCK, JR., JULES I. LEVINE, and GRAYSON B. MILLER, JR. ....	701
<i>Pseudomonas cepacia</i> : Implications of Epidemic Nosocomial Colonization. WILLIAM J. MARTONE, CHARLES A. OSTERMAN, KAREN A. FISHER, and RICHARD P. WENZEL. ....	708
Contaminated Breast Milk: A Source of Klebsiella Bacteremia in a Newborn Intensive Care Unit. LEIGH G. DONOWITZ, FREDERIC J. MARSIK, KAREN A. FISHER, and RICHARD P. WENZEL. ....	716
Program for Surveillance and Intervention in Specific Problem Areas of Nosocomial Infections. LARS O. KALLINGS .....	721
Control of Infection in the Hospital: Problems in Surgery and the Management of Burns. E. J. L. LOWBURY. ....	728
Wound Infection Surveillance. PETER CRUSE. ....	734
Preventing Nosocomial Infection through the Use of Effective Management Techniques. BARBARA A. TERRY. ....	738
Discussion .....	742

## Session III

Evaluation of Antibiotic Usage: A Comprehensive Look at Alternative Approaches. CALVIN M. KUNIN. ....	745
Antibiotic Use on the Surgical Services of Two Jerusalem Hospitals, as Determined by Surveillance and Influenced by an Intervention Program. M. SHAPIRO, T. SACKS, E. SIMCHEN, J. MICHEL, and B. RUDENSKY. ....	754
Environmental Factors in Nosocomial Infection—A Selective Focus. JOHN E. MCGOWAN, JR. ....	760
Do You Practice What You Preach? ELIZABETH A. JENNER. ....	770
The Usefulness of a Conceptual Model in the Study of the Efficacy of Infection Surveillance and Control Programs. ROBERT W. HALEY. ....	775
Discussion .....	781

## Session IV

Nosocomial Infection Control: Role of the Hospital Administrator. PHILIP S. BRACHMAN and ROBERT W. HALEY. ....	783
The Role of the Hospital Administrator in the Control of Nosocomial Infections. LEON EPSTEIN .....	785
Cost and Benefit in Control of Nosocomial Infection: Methods for Analysis. JOHN E. MCGOWAN, JR. ....	790

## Session V

International Symposium on Control of Nosocomial Infections: Synthesis and Summary. THEODORE C. EICKHOFF. ....	798
--	-----



Agents of Mycobacterial Variation. EDITH MANKIEWICZ.....	926
Antigenic Relationships among Mycobacterial Species Studied by Modified-Rocket and Crossed Immunoelectrophoresis. SOTIROS D. CHAPARAS.....	934
Mycobacterial Sensitins: Where Are We Now? MOGENS MAGNUSSON.....	944
Characterization of Plasmids from Strains of <i>Mycobacterium avium-intracellulare</i> . JACK T. CRAWFORD, M. DONALD CAVE, and JOSEPH H. BATES.....	949
Session IV: Animal Infections	
The Value of Animal Models for Study of Infection Due to Atypical Mycobacteria. The Schaefer Memorial Lecture. GERTRUD MEISSNER.....	953
Mycobacterial Infections in Animals. CHARLES O. THOEN, ALFRED G. KARLSON, and ELMER M. HIMES.....	960
Experimental Infections with <i>Mycobacterium intracellulare</i> . PATTISAPU R. GANGADHARAM, PHILIP F. PRATT, and PAUL T. DAVIDSON.....	973
Pathogenicity and Immunogenicity of Atypical Mycobacteria for Calves: A Short Summary. J. BERG JØRGENSEN.....	979
Immune Responses to Atypical Mycobacterial Lung Infections. FRANK M. COLLINS and SUSAN R. WATSON.....	981
Session V: Epidemiology	
Recent Experience in the Epidemiology of Disease Caused by Atypical Mycobacteria. HOWARD GRUFT, JOSEPH O. FALKINHAM III, and BRUCE C. PARKER.....	990
Epidemiologic Studies of Lung Disease Due to Mycobacteria Other than <i>Mycobacterium tuberculosis</i> in Japan. MICHIO TSUKAMURA, HISAO SHIMOIDE, NOBUHIKO KITA, KEISHI KAWAKAMI, TADAO ITO, NAOTO NAKAJIMA, HIROKO KONDO, YOSHITAKA YAMAMOTO, NOBURU MATSUDA, MASATOSHI TAMURA, KAZUO YOSHIMOTO, NOBUMITSU SHIROTA, and AKIHIKO KUSE.....	997
Epidemiology of Mycobacteria Other than Tubercle Bacilli in South Africa. H. H. KLEEBERG	1008
<i>Mycobacterium avium-intracellulare</i> Complex Serovars Isolated in South Africa from Humans, Swine, and the Environment. ELLEN E. NEL.....	1013
The Epidemiology of Opportunist Mycobacterial Infections in Wales, 1952-1978. PETER A. JENKINS.....	1021
<i>Mycobacterium kansasii</i> Infections in The Netherlands: A Brief Summary. H. W. B. ENGEL, L. C. BERWALD, B. W. LINDEBOOM, and A. H. HAVELAAR.....	1024
Session VI: Clinical Aspects	
Editorial. When is an Infection Disease? EMANUEL WOLINSKY.....	1025
Chemotherapy for Pulmonary Disease Due to <i>Mycobacterium kansasii</i> : Efficacies of Some Individual Drugs. CHAI H. AHN, JAMES R. LOWELL, SAM S. AHN, SUZANNE AHN, and GEORGE A. HURST.....	1028
Treatment of Pulmonary Disease Due to <i>Mycobacterium kansasii</i> : Recent Experience with Rifampin. WILLY PEZZIA, JAMES W. RALEIGH, MARGARET C. BAILEY, ELIZABETH A. TOTH, and JULIAN SILVERBLATT.....	1035
<i>Mycobacterium simiae</i> and Related Mycobacteria. J. G. WEISZFEILER, V. KARASSEVA, and E. KARCZAG.....	1040
Spectrum of Clinical Disease in Pulmonary Infection with <i>Mycobacterium avium-intracellulare</i> . DAVID Y. ROSENZWEIG and DONALD P. SCHLUETER.....	1046

Treatment of Disease Due to *Mycobacterium intracellulare*. PAUL T. DAVIDSON, VINOD KHANUO, MARIAN GOBLE, and THOMAS S. MOULDING. .... 1052

Disease Due to *Mycobacterium intracellulare*: Its Possible Association with Human Leukocyte Antigens. ANUP K. CHAKRABORTY, PRADEEP B. DAMLE, PAUL T. DAVIDSON, and ROBERT T. McCALMON. .... 1060

Surgical Management of Pulmonary Disease Due to *Mycobacterium avium-intracellulare*. RAYMOND F. CORPE. .... 1064

Clinical Usefulness of Amikacin and Doxycycline in the Treatment of Infection Due to *Mycobacterium fortuitum* and *Mycobacterium chelonae*. JOSEPH R. DALOVISIO, GEORGE A. PANKEY, RICHARD J. WALLACE, and DAN B. JONES. .... 1068

Editorial. Atypical Mycobacterial Infections in Children. KATHARINE H. K. HSU. .... 1075

Mixed Mycobacterial Infections. J. G. WEISZFEILER and V. KARASSEVA. .... 1081

Nontuberculous Mycobacteria in Sweden: A Brief Summary. INGELA SJÖGREN. .... 1084

Pulmonary Infection Caused by Atypical Mycobacteria: A Report of 24 Cases in Thailand. NADDA SRIYABHAYA and SRIBUSAYA WONGWATANA. .... 1085

Pulmonary Disease Due to Atypical Mycobacteria: A Retrospective Study from South India. C. V. RAMAKRISHNAN. .... 1090

Discussion. .... 1093

Classics in Infectious Diseases

The Relationship of "Atypical" Acid-Fast Bacteria to Human Disease: A Preliminary Report. ALICE TIMPE and ERNEST H. RUNYON. .... 1098

Errata (Zlydnikov, D. M. et al. 3:408-421). .... 1104

Volume 3 • November-December 1981 • Number 6

**Contents**

**Review Articles**

Antibiotic Resistance of *Salmonella* in Europe and the United States. CHARLES E. CHERUBIN. . 1105

The Significance of Iron in Infection. J. J. BULLEN. .... 1127

Actinomycetoma in the United States. ROBERT R. TIGHT and MARILYN S. BARTLETT. .... 1139

Cytomegalovirus Infections Following Renal Transplantation. JERRY GLENN. .... 1151

Radiolabeled Microorganisms: Comparison of Different Radioisotopic Labels. RAJ KISHORE. .... 1179

Isolation and Characterization of a Human Fibroblast Interferon Gene and Its Expression in *Escherichia coli*. RIK DERYNCK, RENÉ DEVOS, ERIK REMAUT, ERIK SAMAN, PATRICK STANSSENS, JAN TAVERNIER, GUIDO VOLCKAERT, JEAN CONTENT, ERIK DE CLERCQ, and WALTER FIERIS. .... 1186

**Serial Feature**

Abnormal Phagocyte Chemotaxis: Pathophysiology, Clinical Manifestations, and Management of Patients. JOHN I. GALLIN. .... 1196

The Role of Cell-Mediated Immunity in Bacterial Infections. HELMUT HAHN and STEFAN H. E. KAUFMANN .....	1221
Historical Article	
Who Introduced Typhoid Vaccination: Almroth Wright or Richard Pfeiffer? DIETER H. M. GRÖSCHEL and RICHARD B. HORNICK .....	1251
Correspondence	
Alternatives to Water Chlorination. HANS H. NEUMANN .....	1255
Reviewers for Volume 3 .....	1258
Index to Volume 3 .....	1261

*Volume 3* • *November-December 1981* • *Supplement*

## Contents

Introduction to the Symposium. ROBERT I. WISE .....	S199
Session I: History, Bacteriology, and Animal Toxicity	
Introduction to Vancomycin. RICHARD S. GRIFFITH .....	S200
Structural Features of Vancomycin. RALPH R. PFEIFFER .....	S205
The Antibacterial Action of Vancomycin. CHATRCHAI WATANAKUNAKORN .....	S210
Effects of Antibiotic-Diuretic Interactions in the Guinea Pig Model of Ototoxicity. ROBERT E. BRUMMETT .....	S216
Toxicology of Vancomycin in Laboratory Animals. JOHN S. WOLD and STANLEY A. TURNIPSEED .....	S224
Session II: Clinical Pharmacology and Clinical Use	
Pharmacokinetics of Vancomycin in Normal Subjects and in Patients with Reduced Renal Function. ROBERT C. MOELLERING, JR., DONALD J. KROGSTAD, and DAVID J. GREENBLATT ...	S230
Vancomycin Therapy in Severe Staphylococcal Infections. WILLIAM M. M. KIRBY .....	S236
Evaluation of Antimicrobial Agents in the Rabbit Model of Endocarditis. MERLE A. SANDE .....	S240
Vancomycin Therapy for Infective Endocarditis. JOSEPH E. GERACI and WALTER R. WILSON .....	S250
Antibiotic Prophylaxis in Cancer Patients: Regimens of Oral, Nonabsorbable Antibiotics for Prevention of Infection During Induction of Remission. GERALD P. BODEY .....	S259
Pharmacokinetics of Vancomycin in Anuria. B. A. CUNHA, R. QUINTILIANI, J. M. DEGLIN, M. W. IZARD, and C. H. NIGHTINGALE .....	S269
Treatment of Antibiotic-Associated Enterocolitis with Vancomycin. ROBERT FEKETY, JOSEPH SILVA, JOHN ARMSTRONG, MARIA ALLO, ROBERT BROWNE, JOHN EBRIGHT, RODNEY LUSK, GARY RIFKIN, and RENU TOSHNIWAL .....	S273



Pharmacology and Efficacy of Vancomycin for Staphylococcal Infections in Children. Urs B. SCHAAD, JOHN D. NELSON, and GEORGE H. MCCrackEN, JR .....	S282
Vancomycin for Treatment of Bacterial Meningitis. DIETER W. GUMP .....	S289

Summary

The Vancomycin Symposium: Summary and Comments. ROBERT I. WISE .....	S293
--	------



